Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Active not recruiting 4Completed 2Withdrawn 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

vandetanib 9Everolimus 4Sorafenib 3sargramostim 2cabozantinib 2Trastuzumab 2Sunitinib 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pembrolizumab 1pazopanib 1pasireotide 1nintedanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1fluorodopa F 18 1cixutumumab 1anlotinib 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Medullary × cabozantinib × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled 20 charts
CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡